Skip to main content
Equibles
VYGR logo

VYGR · Voyager Therapeutics, Inc. · Metrics

Track VYGR — free

Use VYGR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VYGR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.73 -0.02 (-1.14%) At close · Oct 27 Q4 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$107.83M
Shares
61.62M
Volume · Oct 27 1.27M Avg daily vol (3M) 639.33K

VYGR metrics

83 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.73
Market cap
$107.83M

Price action

20 metrics
Price change (1W)
-14.6%
Price change (30D)
-35.2%
Price change (3M)
-43.4%
Price change (6M)
-53.5%
Price change (YTD)
-55.5%
Price change (1Y)
-62.4%
Trailing year
Price change (5Y)
-53.0%
52-week high
$5.00
52-week low
$1.74
Change from 52-week high
-65.0%
Change from 52-week low
+0.6%
Annualized volatility
59.7%
Annualized volatility (3M)
58.5%
Beta
1.4
RSI (14D)
26.7
Price vs SMA 50
-38.3%
Price vs SMA 200
-50.0%
Avg volume (3M)
630,770
Relative volume
2.6
Average dollar volume
$1.71M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.1×
reciprocal yield 32.5%
P / book
0.7
reciprocal yield 145.7%
FCF yield
-114.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-101.6%

Historical valuation

8 metrics
P / E historical average (3Y)
13.3×
reciprocal yield 7.5%
P / E historical average (5Y)
13.3×
reciprocal yield 7.5%
EV / revenue historical average (3Y)
2.1×
reciprocal yield 46.9%
EV / revenue historical average (5Y)
1.7×
reciprocal yield 60.1%
EV / EBIT historical average (3Y)
1.9×
reciprocal yield 52.3%
EV / EBIT historical average (5Y)
1.7×
reciprocal yield 57.5%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-10

Profitability

9 metrics
Gross margin
—
Operating margin
-340.1%
Trailing 12 months
Net margin
-312.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$117.19M
Net income (TTM)
−$107.73M
Trailing 12 months
Diluted EPS (TTM)
$-1.81
FCF margin
-352.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.58
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.97
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.81
Operating cash flow per diluted share (TTM)
$-2.03
Free cash flow per diluted share (TTM)
$-2.04
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.00
Stock compensation per diluted share (TTM)
$0.20
Book value per share
$3.32

Growth

11 metrics
Revenue growth YoY
-39.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$34.46M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
-0.4%
Revenue CAGR (5Y)
-25.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-69.8%
Return on assets
-54.5%
Debt / equity
—
Current ratio
7.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$121.42M
Quick ratio
7.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$116.34M
Latest balance sheet
Cash & equivalents
$35.77M
Total assets
$197.75M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$120.57M
Capital expenditures (TTM)
$847,000
R&D (TTM)
$118.46M
SG&A (TTM)
—
Stock compensation (TTM)
$11.90M
R&D / revenue
343.8%
Stock compensation / revenue
34.5%

Ownership (13F)

9 metrics
13F filers
136
13F filer change QoQ
+1
Institutional ownership
57.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
30.1%
Private-fund adviser ownership
29.6%
Active holders' share change QoQ
+6.8%
Holder tenure
11.8
Price vs estimated holder cost
-27.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.1%

Short interest

3 metrics
Short interest
5.9%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1640266 CUSIP 92915B106 13F (30d) 10 filings 10 filers Visit website Investor relations